• News
    • Opinion Editorial
    • Videos
    • Podcasts
  • Community
    • Members
  • Discussion
  • Groups
    • View All
    • Why Join?
  • Write for us
    Sign in Sign up


    • News
      • Opinion Editorial
      • Videos
      • Podcasts
    • Community
      • Members
    • Discussion
    • Groups
      • View All
      • Why Join?
    • Write for us
    Sign in Sign up

    Category: News

    Fertility Specialist at Sheba Medical Center Studying Impact of Pfizer COVID-19 Vaccine on Male Fertility

    Fertility Specialist at Sheba Medical Center Studying Impact of Pfizer COVID-19 Vaccine on Male Fertility

    Unfounded claims have attempted to correlate the mRNA-based vaccines rapidly developed to address COVID-19 infection and fertility in both men and women. According to Dr. Jigal…

    TrialSite Staff
    TrialSite Staff April 17, 2021
    0 Comments
    Antequera Hospital Prepares Study Startup for COVID-19 Vaccine Trial Targeting Children (6mo-12 yrs.) & Pregnant Women

    Antequera Hospital Prepares Study Startup for COVID-19 Vaccine Trial Targeting Children (6mo-12 yrs.) & Pregnant Women

    The interest in the mRNA-based vaccine BNT162b2 developed by Pfizer and Germany’s BioNTech continues to rise in Europe with mounting concerns on the European continent…

    TrialSite Staff
    TrialSite Staff April 17, 2021
    0 Comments
    Fluvoxamine The Federal Government Should Invest in Research for Early Stage COVID-19 Treatment

    Fluvoxamine: The Federal Government Should Invest in Research for Early Stage COVID-19 Treatment

    A common selective serotonin reuptake inhibitor and σ-1 receptor agonist, mounting data indicates that fluvoxamine prevents clinical deterioration in outpatients with acute COVID-19. This finding is…

    TrialSite Staff
    TrialSite Staff April 16, 2021
    2 Comments
    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2…

    TrialSite Staff
    TrialSite Staff April 16, 2021
    0 Comments
    Meridian Partners with Family Practice & Expands Research as a Care Option into Lincoln Nebraska

    Meridian Partners with Family Practice & Expands Research as a Care Option into Lincoln Nebraska

    A leading trial site organization has opened up a new site, now centering around a family practice in Lincoln, Nebraska. Lincoln Medical Education Partnership has been offering…

    TrialSite Staff
    TrialSite Staff April 16, 2021
    0 Comments
    COVID-19 Trial Site Improvements Not So Fast According to Advarra Site Activation Study

    COVID-19 Trial Site Improvements? Not So Fast, According to Advarra Site Activation Study

    One of the largest vendors providing regulatory review solutions, research quality, compliance consulting services, and clinical site technologies, recently shared the publication of The State of Clinical…

    TrialSite Staff
    TrialSite Staff April 16, 2021
    0 Comments
    NIAID to Spend $24m for Year 1 of New Influenza Trial Site Network

    NIAID to Spend $24m for Year 1 of New Influenza Trial Site Network

    The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has established a network of research sites to study…

    TrialSite Staff
    TrialSite Staff April 16, 2021
    0 Comments
    Is Official Ivermectin Petition Going to Spark an Expert Grass-roots Movement for Early Covid-19 Treatment in Canada

    Is Official Ivermectin Petition Going to Spark an Expert Grass-roots Movement for Early Covid-19 Treatment in Canada?

    Canada, as pretty much every other Western country, hasn’t narrowed down a treatment for early onset COVID-19. TrialSite News has been extensively reporting on various…

    TrialSite Staff
    TrialSite Staff April 16, 2021
    3 Comments
    GSK Halts Two Mid-Stage Oncology Trials Assessing ICOS Agonist Feladilimab

    GSK Halts Two Mid-Stage Oncology Trials Assessing ICOS Agonist Feladilimab

    GlaxoSmithKline announced the decision to halt the phase 2 INDUCE-3 and INDUCE-4 trials, which are evaluating its investigational inducible T cell co-stimulatory (ICOS) agonist feladilimab…

    TrialSite Staff
    TrialSite Staff April 15, 2021
    0 Comments
    Sage Therapeutics and Biogen Announce SAGE-324 Reduced Tremor in Phase 2 KINETIC Study

    Sage Therapeutics and Biogen Announce SAGE-324 Reduced Tremor in Phase 2 KINETIC Study

    Sage Therapeutics and Biogen reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of patients with essential tremor (ET). The…

    TrialSite Staff
    TrialSite Staff April 15, 2021
    0 Comments
    Load More

    Read more about…

    Alzheimer Alzheimer's Disease Artificial Intelligence Autoimmune Disease Breast Cancer Cancer Cardiovascular Challenging Results China Clinical Research Clinical Research as a Care Option Clinical Trials CNS Coronavirus covid-19 COVID-19 Dementia Diabetes Digital Health Digital Media FDA Gene Therapy Immunotherapy India Investigator Content Investigator Profiles Investor Watch Ivermectin Leading Pharma Leading Sites Neurology NIH Oncology Patient Recruitment Pharma Watch Positive Results Price Watch Prostate Cancer Research SARS-CoV-2 Site Challenges Site Success Site Watch UK Vaccine

    About Us

    TRIALSITE NEWS IS  DEDICATED TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

    © 2021 - Trial Site News
    • Terms of Service
    • Privacy Policy

    TrialSite News
    159 W Broadway, Suite 200
    Salt Lake City, UT 84101

    Report Content

    Harassment or bullying behavior
    Contains mature or sensitive content
    Contains misleading or false information
    Contains abusive or derogatory content
    Anything overly promotional selling products or services

    Block Member?

    Please confirm you want to block this member.

    You will no longer be able to:

    • See blocked member's posts
    • Mention this member in posts
    • Invite this member to groups
    • Message this member
    • Add this member as a connection

    Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.